These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism. Epstein M Lancet Diabetes Endocrinol; 2015 Dec; 3(12):993-1003. PubMed ID: 26429402 [TBL] [Abstract][Full Text] [Related]
18. Role of mineralocorticoid receptor antagonists in cardiovascular disease. Ferrario CM; Schiffrin EL Circ Res; 2015 Jan; 116(1):206-13. PubMed ID: 25552697 [TBL] [Abstract][Full Text] [Related]
19. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Struthers AD; MacDonald TM Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063 [TBL] [Abstract][Full Text] [Related]
20. The role of aldosterone receptor blockade in the management of cardiovascular disease. Liew D; Krum H Curr Opin Investig Drugs; 2002 Oct; 3(10):1468-73. PubMed ID: 12431020 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]